{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:21:26Z","timestamp":1794558086630,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-024-02184-8","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T23:45:41Z","timestamp":1733442341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy"],"prefix":"10.1186","volume":"23","author":[{"given":"Huaijin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangqin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Kleeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiushan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaofei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2184_CR1","doi-asserted-by":"crossref","unstructured":"Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024.","DOI":"10.3322\/caac.21834"},{"key":"2184_CR2","doi-asserted-by":"crossref","unstructured":"Zhao Y, et al. Chinese expert consensus on minimally invasive radical surgery for pancreatic ductal adenocarcinoma (version 2022). Journal of Pancreatology. 2022;5(3):111\u20137.","DOI":"10.1097\/JP9.0000000000000097"},{"key":"2184_CR3","doi-asserted-by":"crossref","unstructured":"Wu W, et al. Real-world study of surgical treatment of pancreatic cancer in China: annual report of China Pancreas Data Center (2016\u20132020). Journal of Pancreatology. 2022;5(1):1\u20139.","DOI":"10.1097\/JP9.0000000000000086"},{"issue":"19","key":"2184_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"2","key":"2184_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/JP9.0000000000000093","volume":"5","author":"ZH Xu","year":"2022","unstructured":"Xu ZH, et al. Insight of pancreatic cancer: recommendations for improving its therapeutic efficacy in the next decade. Journal of Pancreatology. 2022;5(2):58\u201368.","journal-title":"Journal of Pancreatology"},{"issue":"7986","key":"2184_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","volume":"623","author":"N Caronni","year":"2023","unstructured":"Caronni N, et al. IL-1beta(+) macrophages fuel pathogenic inflammation in pancreatic cancer. Nature. 2023;623(7986):415\u201322.","journal-title":"Nature"},{"issue":"1","key":"2184_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu Q, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22(1):28.","journal-title":"Mol Cancer"},{"issue":"8","key":"2184_CR8","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00262-020-02542-7","volume":"69","author":"Q Liu","year":"2020","unstructured":"Liu Q, et al. Combined blockade of TGf-beta1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Cancer Immunol Immunother. 2020;69(8):1477\u201392.","journal-title":"Cancer Immunol Immunother"},{"key":"2184_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.607209","volume":"8","author":"S Yang","year":"2020","unstructured":"Yang S, Liu Q, Liao Q. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming. Front Cell Dev Biol. 2020;8: 607209.","journal-title":"Front Cell Dev Biol"},{"key":"2184_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12935-017-0437-3","volume":"17","author":"Q Liu","year":"2017","unstructured":"Liu Q, Liao Q, Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int. 2017;17:68.","journal-title":"Cancer Cell Int"},{"issue":"8000","key":"2184_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41586-023-06950-4","volume":"626","author":"Z Deng","year":"2024","unstructured":"Deng Z, et al. The nuclear factor ID3 endows macrophages with a potent anti-tumour activity. Nature. 2024;626(8000):864\u201373.","journal-title":"Nature"},{"issue":"5","key":"2184_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651\u201362.","journal-title":"Lancet Oncol"},{"key":"2184_CR13","doi-asserted-by":"crossref","unstructured":"Gomez-Roca, C., et al., Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naive or experienced for immune checkpoint blockade. J Immunother Cancer, 2022. 10(5).","DOI":"10.1136\/jitc-2021-004076"},{"issue":"8","key":"2184_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2184_CR15","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1136\/gutjnl-2018-316128","volume":"68","author":"J Luna","year":"2019","unstructured":"Luna J, et al. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut. 2019;68(8):1465\u201376.","journal-title":"Gut"},{"key":"2184_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216286","volume":"568","author":"AR Mekapogu","year":"2023","unstructured":"Mekapogu AR, et al. HGF\/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis. Cancer Lett. 2023;568: 216286.","journal-title":"Cancer Lett"},{"key":"2184_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canlet.2021.04.029","volume":"512","author":"S Mori","year":"2021","unstructured":"Mori S, et al. Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. Cancer Lett. 2021;512:51\u20139.","journal-title":"Cancer Lett"},{"key":"2184_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.diff.2022.10.001","volume":"128","author":"ZN Mohd Yasin","year":"2022","unstructured":"Mohd Yasin ZN, et al. Macrophage polarization in THP-1 cell line and primary monocytes: A systematic review. Differentiation. 2022;128:67\u201382.","journal-title":"Differentiation"},{"key":"2184_CR19","doi-asserted-by":"crossref","unstructured":"Qi, C., et al., CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. J Hematol Oncol, 2023. 16(1): p. 102.","DOI":"10.1186\/s13045-023-01491-9"},{"issue":"10","key":"2184_CR20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","volume":"9","author":"K Feng","year":"2018","unstructured":"Feng K, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2018;9(10):838\u201347.","journal-title":"Protein Cell"},{"issue":"2","key":"2184_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neo.2021.12.005","volume":"24","author":"HH Lee","year":"2022","unstructured":"Lee HH, et al. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models. Neoplasia. 2022;24(2):98\u2013108.","journal-title":"Neoplasia"},{"issue":"7","key":"2184_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1200\/JCO.1991.9.7.1251","volume":"9","author":"A Faradji","year":"1991","unstructured":"Faradji A, et al. Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol. 1991;9(7):1251\u201360.","journal-title":"J Clin Oncol"},{"key":"2184_CR23","doi-asserted-by":"crossref","unstructured":"Lopez, M., et al., Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study. J Immunother (1991), 1992. 11(3): p. 209\u201317.","DOI":"10.1097\/00002371-199204000-00008"},{"issue":"4","key":"2184_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jlb.64.4.419","volume":"64","author":"R Andreesen","year":"1998","unstructured":"Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol. 1998;64(4):419\u201326.","journal-title":"J Leukoc Biol"},{"key":"2184_CR25","doi-asserted-by":"crossref","unstructured":"Pan, Q., et al., Chimeric Antigen Receptor Macrophages Target and Resorb Amyloid Plaques in a Mouse Model of Alzheimer's Disease. bioRxiv, 2023.","DOI":"10.1101\/2023.04.28.538637"},{"issue":"10","key":"2184_CR26","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s00262-023-03490-8","volume":"72","author":"Z Duan","year":"2023","unstructured":"Duan Z, et al. Chimeric antigen receptor macrophages activated through TLR4 or IFN-gamma receptors suppress breast cancer growth by targeting VEGFR2. Cancer Immunol Immunother. 2023;72(10):3243\u201357.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2184_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12885-022-10500-y","volume":"23","author":"X Hu","year":"2023","unstructured":"Hu X, et al. Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. BMC Cancer. 2023;23(1):331.","journal-title":"BMC Cancer"},{"issue":"10","key":"2184_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","volume":"121","author":"W Zhang","year":"2019","unstructured":"Zhang W, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121(10):837\u201345.","journal-title":"Br J Cancer"},{"issue":"21","key":"2184_CR29","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1158\/1078-0432.CCR-21-0765","volume":"27","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, et al. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021;27(21):5781\u201392.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2184_CR30","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.22.00739","volume":"41","author":"DR Camidge","year":"2023","unstructured":"Camidge DR, et al. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023;41(5):1105\u201315.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2184_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","volume":"21","author":"Y Huo","year":"2023","unstructured":"Huo Y, et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J Transl Med. 2023;21(1):225.","journal-title":"J Transl Med"},{"issue":"2","key":"2184_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/JP9.0000000000000091","volume":"5","author":"C Wang","year":"2022","unstructured":"Wang C, Wu Y, Wang W. Neoadjuvant therapy for resectable pancreatic cancer: a narrative review. Journal of Pancreatology. 2022;5(2):69\u201377.","journal-title":"Journal of Pancreatology"},{"issue":"8","key":"2184_CR33","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, et al. Pancreatic cancer: Advances and challenges. Cell. 2023;186(8):1729\u201354.","journal-title":"Cell"},{"key":"2184_CR34","doi-asserted-by":"crossref","unstructured":"Pan, K.,et al., CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Journal of experimental & clinical cancer research ,2022. CR, 41(1), 119.","DOI":"10.1186\/s13046-022-02327-z"},{"issue":"1","key":"2184_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Chen P, Ma W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024;13(1):76.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2184_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","volume":"23","author":"N Li","year":"2024","unstructured":"Li N, Geng S, Dong ZZ, et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol Cancer. 2024;23(1):117.","journal-title":"Mol Cancer"},{"key":"2184_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Front Immunol. 2021;12: 783305.","journal-title":"Front Immunol"},{"issue":"5","key":"2184_CR38","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/cancers15051597","volume":"15","author":"G Schepisi","year":"2023","unstructured":"Schepisi G, Gianni C, Palleschi M, et al. The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. Cancers (Basel). 2023;15(5):1597.","journal-title":"Cancers (Basel)"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-024-02184-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:02:55Z","timestamp":1733443375000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-024-02184-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2184"],"URL":"https:\/\/doi.org\/10.1186\/s12943-024-02184-8","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"2 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of Peking Union Medical College Hospital approved this animal study (February 15th, 2023, XHDW-2022\u2013126).Human blood for this study was ethically sourced and analyzed with approval from the Roc Rock Biotechnology Ethics Committee (approval number 2022,002). Research adhered to medical standards and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"270"}}